Litao Zhang

Dr. Litao Zhang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2015 in Persoonia - Molecular Phylogeny and Evolution of Fungi
Verified
Journal Article
Open access
YZY. Zhang
Y. Zhang
FHF. Hagen
F. Hagen
BSB. Stielow
B. Stielow
Anderson Messias RodriguesAnderson Messias Rodrigues
Anderson Messias Rodrigues
KSK. Samerpitak
K. Samerpitak
SHSybren Sijbrand de Hoog
Sybren Sijbrand de Hoog
Pathology to vertebrate hosts has emerged repeatedly in the order Ophiostomatales. Occasional infections have been observed in Sporothrix mexicana at a low level of virulence, while the main pathogenic species cluster in a derived clade around S. schenckii s.str. In this paper, phylogeny and epidemiology of the members of this clade were investigated for 99 clinical and 36 environmental strains using four genetic loci, viz. rDNA ITS and partial CAL, TEF1, and TEF3; data are compared with amplified fragment length polymorphism (AFLP) genotyping. The four main species of the pathogenic clade were recognised. The species proved to show high degrees of endemicity, which enabled interpretation of literature data where live material or genetic information is lacking. The clade of four species comprised nine subclusters, which often had limited geographic distribution and were separate from each other in all partitions, suggesting low degrees of interbreeding between populations. In contrast, S. globosa exhibited consistent global distribution of identical AFLP types, suggesting another type of dispersal. Sporothrix brasiliensis is known to be involved in an expanding zoonosis and transmitted by cats, whereas S. globosa infections originated from putrid plant material, causing a sapronosis. Sporothrix schenckii s.str., the most variable species within the clade, also had a plant origin, with ecological similarities to that of S. globosa. A hypothesis was put forward that highly specific conditions in the plant material are required to promote the growth of Sporothrix. Fermented, self-heated plant debris may stimulate the thermodependent yeast-like invasive form of the fungus, which facilitates repeated infection of mammals.

13 June 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
PCPeng Cao
Peng Cao
WXWenjing Xu
Wenjing Xu
LZLitao Zhang
Litao Zhang
Background: Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease of the skin. First-line treatment of systemic corticosteroids may cause serious adverse events. Rituximab, omalizumab, and dupilumab should be explored as alternative treatment options to improve outcomes. Objective: To systematically review the rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid. Methods: A PubMed, Embase, Web of Science, and Cochrane library search were conducted on March 10, 2022. A total of 75 studies were included using Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Results: Use of rituximab (n=122), omalizumab (n=53) and dupilumab (n=36) were reported in 211 patients with BP. Rituximab led to complete remission in 70.5% (n=86/122) and partial remission in 23.8% (n=29/122) of patients within 5.7 months, with a recurrence rate of 20.5% (n=25/122). 9.0% (n=11/122) of patients died and infection (6.6%, n=8/122) was the most common adverse event. Omalizumab led to complete remission in 67.9% (n=36/53) and partial remission in 20.8% (n=11/53) of patients within 6.6 months, with a recurrence rate of 5.7% (n=3/53). 1.9% (n=1/53) of patients died and thrombocytopenia (1.9%, n=1/53) was observed as the most common adverse event. Dupilumab led to complete remission in 66.7% (n=24/36) and partial remission in 19.4% (n=7/36) of patients within 4.5 months of treatment without any reported adverse events, with a recurrence rate of 5.6% (n=2/36). Conclusions: Rituximab, omalizumab, and dupilumab have similar clinical benefits for BP patients. However, rituximab resulted in higher recurrence rates, adverse events, and mortality rates. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022316454.


18 May 2021 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
SSShuya Sun
Shuya Sun
GCGuizhen Chang
Guizhen Chang
LZLitao Zhang
Litao Zhang
Accumulated evidences support the fetus’s intestinal flora unbalance is associated with the development of allergic diseases. Probiotic supplements in pregnancy and childhood might prevent atopic diseases. The aim of this systematic review and meta-analysis was to evaluate the effect of probiotic supplementation during pregnancy and early infancy in preventing eczema, atopic eczema, and other allergic diseases. We also explored whether different probiotic strains or intervention objects affected the antiallergic effect of probiotics and the prevention atopy effect of the long-term period. Fixed-effect models were used, and random-effects models where significant heterogeneity was present. Results were expressed as odds ratios (ORs) with a 95% confidence interval (CI). Twenty-one studies were included in the meta-analysis. The probiotics group had a significantly lower risk of eczema and atopic eczema compared to controls, especially those treated with probiotic combinations. Mothers’ probiotics intake significantly contributed to reducing the risk of eczema as well as atopic eczema. What’s more, probiotics seemed effective on eczema prevention ≤2 years of age, but against atopic eczema after 1 of age year. No significant difference in terms of prevention of asthma, rhinitis, wheeze, allergic diseases and sensation. In brief, a probiotic supplement is expected to become a novel potential strategy for infant eczema and atopic eczema.

20 January 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
PCPeng Cao
Peng Cao
WXWenjing Xu
Wenjing Xu
SJShuyi Jiang
Shuyi Jiang
LZLitao Zhang
Litao Zhang
Background: Conventional treatment techniques have limited efficacy and more side effects in the treatment of prurigo nodularis. The better alternative treatment option for better outcomes of the disease is dupilumab.Objective: The objective of this study was to systematically review dupilumab-related treatment outcomes in prurigo nodularis.Methods: Several databases like Embase, PubMed, Web of Science, and Cochrane library were searched for data acquisition on October 8, 2022. Based on Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, 24 publications were included in this study.Results: After 4,12,16 and more than 16 weeks of dupilumab treatment, 8.3% (n=5/60), 34.4% (n=11/32), 3.6% (n=2/56), and 45.3% (n=29/64) of patients had complete remission, respectively. In addition, 85.0% (n=51/60), 59.4% (n=19/32), 83.9% (n=47/56), and 43.8% (n=28/64) had partial remission, respectively. Moreover, 6.7% (n=4/60), 6.3% (n=2/32), 12.5% (n=7/56), and 10.9% (n=7/64) showed no remission, respectively, and significant reduction of numeric rating scale itch intensity (from 9.0 to 4.9, 2.1, 2.8, 0.9) was attained. There were no serious adverse events observed during treatment, but the most common event observed was conjunctivitis (12.6%, n=15/119).Conclusions: Dupilumab has definite effectiveness and safety in prurigo nodularis treatment.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO, identifier (CRD42022365802).

2 August 2019 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
GCGuizhen Chang
Guizhen Chang
JWJin Wang
Jin Wang
JSJingxin Song
Jingxin Song
ZZZhilong Zhang
Zhilong Zhang
LZLitao Zhang
Litao Zhang
Background A growing number of studies have shown that thiazolidinedoniones(TZD) can be antipsoriatic. Pioglitazone is a representative of the class of antidiabetic drugs known as TZD. TZD can activate nuclear peroxisome proliferator-activated receptors (PPAR)-c. PPARs are expressed on epidermal keratinocytes and exert their effects by promoting the terminal differentiation of keratinocytes, inhibiting epidermal growth, and reducing inflammatory responses. These observations suggest that TZD have potential benefits in the treatment of cutaneous and metabolic pathologies associated with psoriasis. Objective A systematic review and meta-analysis was carried out to evaluate the efficacy of combined Pioglitazone treatment. We point out 3 controversial side effects from administration of Pioglitazone in psoriasis: elevated liver enzymes, weight gain, and nausea. Study selection Randomized, single blind, or double blind, published studies of Pioglitazone compared with placebo, given to patients with plaque psoriasis for 10 weeks or 12 weeks were considered for inclusion in this review. The primary outcomes were 75% or greater improvement in the Psoriasis Area and Severity Index score from baseline (PASI 75) with pioglitazone. Data collection and analysis The systematic literature search was conducted in the PubMed, Embase, Google Scholar, and Cochrane databases from inception up to December20, 2018. Data analysis was done using Revman 5.3. Main results We included 6 studies(3 publications of pioglitazone only; 3 publications of pioglitazone combination therapy) comprising a total of 294 patients (n = 149 with pioglitazone only and n = 145 with pioglitazone combination therapy) in the analysis. There was a significantly PASI 75 response, in the pioglitazone only subgroup as compared to placebo(OR =8.74, 95% CI 3.76–20.31, P < 0.00001), and the pioglitazone combination subgroup as compared to placebo(OR =4.64, 95% CI 2.03–10.60, P < 0.00001), others, the total of pioglitazone as compared to placebo(OR =6.37, 95% CI 3.55–11.43, P < 0.00001), And tests of subgroup differences show: p = 0.29, I2 = 9.5%. The incidence rate of elevated liver enzymes (OR =3.70, 95% CI 0.56–24.31, P =0.99), weight gain(OR =1.44, 95% CI 0.60–3.47, P =0.41) and nausea(OR =0.76, 95% CI 0.23–2.49, P =0.65) were not significantly different compared with the control group. Conclusion Pioglitazone has efficacy for the treatment of plaque psoriasis. There is no significant difference between patients treated with Pioglitazone only or in combination with other therapies. The incidence rate of side effects associated with Pioglitazone treatment such as elevated liver enzymes, weight gain, and nausea were not significantly different compared with the control group.